Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

102.53 -0.14 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

70 71 Next >

Why Pfizer Partner BioNTech Shares Are Rising Today ↗

June 27, 2022

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 6.31% at $142.50 after the company announced its Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response against the...

Via Benzinga

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant ↗

June 27, 2022

Via Benzinga

7 Biotech Stocks With Key Catalysts Coming in July ↗

June 27, 2022

Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.

Via InvestorPlace

BioNTech Whale Trades Spotted ↗

June 17, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades.

Via Benzinga

BioNTech Whale Trades For June 10 ↗

June 10, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades.

Via Benzinga

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

June 25, 2022

From Pfizer Inc.

Via Business Wire

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug ↗

June 23, 2022

BioNTech (NASDAQ: BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular...

Via Benzinga

7 Long-Term Stocks to Buy in a Bear Market ↗

June 20, 2022

These long-term stocks to buy are from defensive sectors, because now is the time to play defense in your stock investing.

Via InvestorPlace

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months ↗

June 17, 2022

Via Benzinga

Pfizer, Moderna Snag FDA OK For Covid Shots In Children At 6 Months Old ↗

June 17, 2022

The decision expands Covid shots out to the last group to become eligible.

Via Investor's Business Daily

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

June 17, 2022

From Pfizer Inc.

Via Business Wire

Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot ↗

June 16, 2022

Via Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Committee Backs Pfizer, Moderna COVID-19 Vaccines For Toddlers, Youngest Children ↗

June 16, 2022

The FDA's Vaccines and Related Biological Products Advisory Committee voted i

Via Benzinga

As Omicron Surges, FDA Mulls Pfizer, Moderna Covid Shots For Babies ↗

June 15, 2022

Pfizer studied a three-dose regimen. Moderna looked at two doses.

Via Investor's Business Daily

The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data ↗

June 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 15 ↗

June 15, 2022

Reuters Warner Bros Discovery To Undergo Major Global Ad Sales Team Restructuring

Via Benzinga

FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report ↗

June 15, 2022

Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.

Via Benzinga

EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters ↗

June 14, 2022

Via Benzinga

Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters ↗

June 14, 2022

Via Benzinga

IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine ↗

June 14, 2022

Here's why its protein-based shot could struggle in the U.S.

Via Investor's Business Daily

Moderna's Pediatric Covid Shot Is On Deck At The FDA: Here's What To Know ↗

June 14, 2022

The FDA's vaccine experts will later vote on whether to recommend the shot.

Via Investor's Business Daily

FDA Backs Pediatric Covid Shots; Here's Why Pfizer, Moderna Shares Crumbled ↗

June 13, 2022

The FDA says Covid shots for children under the age of 5 are safe and effective.

Via Investor's Business Daily

5 Biotech Stocks To Watch During The Week Of June 13 ↗

June 13, 2022

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a...

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, June 13 ↗

June 13, 2022

CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why

Via Benzinga

Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years ↗

June 13, 2022

Via Benzinga

Pfizer/BioNTech's Three-Dose COVID-19 Vaccine Safe, Effective In Younger Kids ↗

June 13, 2022

According to the FDA briefing document, Pfizer Inc (NYSE: PFE) -BioNTech's SE (NASDAQ:

Via Benzinga

Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern ↗

June 13, 2022

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.